Management of Breo (fluticasone propionate/formoterol) in Patients Without Chronic Airway Disease During RSV Infection

Supportive Care for RSV in Healthy Adults

• In adults without underlying COPD or asthma, RSV infection is managed with supportive measures such as supplemental oxygen, adequate hydration, and antipyretics, rather than maintenance respiratory medications 1.

Risks Associated with Inhaled Corticosteroids During Active Infection

• Continuation of inhaled corticosteroids (e.g., fluticasone propionate) in the setting of an active respiratory infection increases the risk of developing pneumonia, a concern that is amplified during RSV infection 2.

Elevated Hospitalization Risk in Asthma Patients with RSV

• Individuals with asthma experience a 7–8‑fold higher risk of RSV‑related hospitalization compared with those without asthma, underscoring the importance of appropriate anti‑inflammatory therapy in this subgroup 1.

Medication Safety: Avoid Unnecessary Continuation of Breo

• In patients lacking a diagnosis of COPD or asthma, continuing Breo “just to be safe” exposes them to medication‑related adverse effects without any therapeutic benefit and should therefore be avoided 2.